DNA Methylation and Transcript Variant Analysis of CDKN2A Exon 2 Despite High Sequence Identity with CDKN2B Exon 2

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• The tumor suppressor p16INK4a, encoded by CDKN2A, is frequently inactivated in cancer.
• Promoter hypermethylation is a common epigenetic cause, but aberrant CDKN2A exon 2 methylation also occurs.
• Analyzing CDKN2A exon 2 methylation is difficult due to sequence similarity with CDKN2B.

Purpose of the Study:

• To develop a novel pyrosequencing assay for accurate analysis of CDKN2A exon 2 DNA methylation.
• To investigate the role of both promoter and exon 2 methylation in regulating CDKN2A expression.
• To apply the assay to glioma and breast cancer cell lines.

Main Methods:

• Developed a pyrosequencing assay with a novel primer set for co-amplification of homologous CDKN2A and CDKN2B regions.
• Quantified CDKN2A proportion to determine methylation levels for CpGs in CDKN2A exon 2.
• Examined promoter methylation, mRNA and protein expression, and other (epi)genetic alterations.

Main Results:

• The assay accurately determined methylation levels for CpGs in CDKN2A exon 2.
• Observed a range of (epi)genetic alterations including homozygous deletions, transcript-specific expression, and exon 2 skipping.
• Both promoter and exon 2 methylation were found to contribute to CDKN2A expression regulation.

Conclusions:

• A novel pyrosequencing method enables accurate analysis of CDKN2A exon 2 methylation.
• Aberrant methylation in both promoter and exon 2 plays a role in CDKN2A regulation in cancer.
• This method is a valuable tool for future cancer research on CDKN2A.